Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Algisyl in Moderate to Severe Heart Failure
NCT03082508Unknown
- Sponsor
- LoneStar Heart
- Start
- Aug 2017
- Primary completion
- Jan 2020
01
Overview
Randomised, open-label trial in heart failure (HF), dilated cardiomyopathy (DCM) and heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by LoneStar Heart. Primary endpoints: Peak VO2 at 6 months and Death or Re-hospitalization for Worsening Heart Failure at 12 months. Status: unknown.
02
Conditions
heart failure (HF)dilated cardiomyopathy (DCM)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT03082508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03082508.